摘要
目的分析格列齐特联合阿卡波糖治疗2型糖尿病(T2DM)的临床效果。方法选择2型糖尿病患者90例,采用随机数字表法将其分为对照组(45例,采用阿卡波糖治疗)和观察组(45例,在对照组基础上采用格列齐特治疗)。对比两组患者血糖[空腹血糖(FPG)、餐后2 h血糖(2 h PG)和糖化血红蛋白(HbA1c)]水平、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-10(IL-10)]及不良反应发生率。结果观察组治疗后FPG(6.03±0.25)mmol/L、2 h PG(7.16±1.05)mmol/L、HbA1c(6.01±0.23)%均低于对照组的(7.12±0.65)mmol/L、(8.97±1.26)mmol/L、(7.13±0.30)%(P<0.05)。观察组治疗后IL-6(5.45±0.19)pg/ml、TNF-α(3.39±0.22)pg/ml、IL-1β(2.26±0.43)pg/ml、IL-10(7.14±0.15)pg/ml均优于对照组的(8.65±0.46)、(6.26±0.19)、(5.69±0.21)、(5.29±0.16)pg/ml(P<0.05)。观察组不良反应发生率0低于对照组的11.11%(P<0.05)。结论格列齐特联合阿卡波糖治疗2型糖尿病能降低患者血糖水平、炎性因子水平以及不良反应发生率,值得推广。
Objective To analyze the clinical effect of gliclazide combined with acarbose in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 90 patients with T2DM were selected and divided into a control group(n=45,treated with acarbose)and an observation group(n=45,treated with gliclazide on the basis of the control group)using a random number table method.Patients in both groups were compared in terms of blood glucose[fasting plasma glucose(FPG),2-h postprandial glucose(2 h PG)and glycated hemoglobin(HbA1c)],inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β),interleukin-10(IL-10)]and the incidence of adverse reactions.Results After treatment,the observation group had FPG of(6.03±0.25)mmol/L,2 h PG of(7.16±1.05)mmol/L,and HbA1c of(6.01±0.23)%,which were lower than those of the control group[(7.12±0.65)mmol/L,(8.97±1.26)mmol/L,and(7.13±0.30)%](P<0.05).After treatment,the observation group had IL-6 of(5.45±0.19)pg/ml,TNF-αof(3.39±0.22)pg/ml,IL-1βof(2.26±0.43)pg/ml,and IL-10 of(7.14±0.15)pg/ml,which were superior to those of the control group[(8.65±0.46),(6.26±0.19),(5.69±0.21),and(5.29±0.16)pg/ml](P<0.05).The incidence of adverse reactions 0 in the observation group was lower than 11.11%in the control group(P<0.05).Conclusion Gliclazide combined with acarbose in the treatment of patients with type 2 diabetes mellitus can reduce blood glucose levels,inflammatory factor levels,and the incidence of complications,and is worthy of promotion.
作者
刘甦
张卫明
陈美格
LIU Su;ZHANG Wei-ming;CHEN Mei-ge(Department of General Medicine,Jianxin Town Health Center,Cangshan District,Fuzhou 350008,China)
出处
《中国现代药物应用》
2025年第20期21-24,共4页
Chinese Journal of Modern Drug Application
